Masimo Corp. Stock
€152.70
Your prediction
Masimo Corp. Stock
Pros and Cons of Masimo Corp. in the next few years
Pros
Cons
Performance of Masimo Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Masimo Corp. | -0.680% | -0.195% | 3.154% | -0.966% | 38.219% | -3.424% | -20.363% |
| Haemonetics Corp. | -2.490% | -9.615% | -10.476% | - | -31.387% | - | - |
| Bio-Rad Labs Inc. A | -2.790% | -1.327% | 0.964% | 2.490% | -10.624% | -45.223% | -51.371% |
| Neogen Corp. | -1.260% | 2.581% | -17.188% | -4.790% | 29.268% | - | - |
Comments
News
This $7 Million Masimo Exit Came Before a 34% Surge on $9.9 Billion Acquisition
On February 17, 2026, Bridger Management disclosed in a Securities and Exchange Commission (SEC) filing that it sold out its entire position in Masimo (NASDAQ:MASI).
According to a Securities and
This Fund Built a $26 Million Stake in a Medical Tech Stock That's Soaring After a $9.9 Billion Deal Announcement
On February 17, 2026, Parkman Healthcare Partners disclosed a new position in Masimo Corporation (NASDAQ:MASI), acquiring 200,000 shares in the fourth quarter worth an estimated $26.01 million at
Naya Capital Adds Masimo Shares
According to an SEC filing dated Feb. 18, Naya Capital Management UK Ltd disclosed a new position in Masimo (NASDAQ:MASI), acquiring nearly 1.6 million shares.
Masimo is a leading provider of


